BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26610046)

  • 1. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.
    Mongiorgi S; Finelli C; Yang YR; Clissa C; McCubrey JA; Billi AM; Manzoli L; Suh PG; Cocco L; Follo MY
    Expert Opin Ther Targets; 2016 Jun; 20(6):677-87. PubMed ID: 26610046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes.
    Xian J; Owusu Obeng E; Ratti S; Rusciano I; Marvi MV; Fazio A; De Stefano A; Mongiorgi S; Cappellini A; Ramazzotti G; Manzoli L; Cocco L; Follo MY
    Cells; 2020 Mar; 9(3):. PubMed ID: 32178280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear inositide signaling in myelodysplastic syndromes.
    Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
    J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in MDS/AML and inositide signalling.
    De Stefano A; Marvi MV; Fazio A; McCubrey JA; Suh PG; Ratti S; Ramazzotti G; Manzoli L; Cocco L; Follo MY
    Adv Biol Regul; 2023 Jan; 87():100955. PubMed ID: 36706610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy.
    Manzoli L; Mongiorgi S; Clissa C; Finelli C; Billi AM; Poli A; Quaranta M; Cocco L; Follo MY
    Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25307310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
    Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
    Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear Inositide Signaling Via Phospholipase C.
    Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
    J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.
    Mongiorgi S; Follo MY; Clissa C; Giardino R; Fini M; Manzoli L; Ramazzotti G; Fiume R; Finelli C; Cocco L
    Curr Top Microbiol Immunol; 2012; 362():235-45. PubMed ID: 23086421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
    Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
    Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
    Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
    Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
    Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
    J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia.
    Ratti S; Mongiorgi S; Rusciano I; Manzoli L; Follo MY
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118649. PubMed ID: 31954103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
    Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes.
    Cocco L; Faenza I; Follo MY; Ramazzotti G; Gaboardi GC; Billi AM; Martelli AM; Manzoli L
    Adv Enzyme Regul; 2008; 48():2-9. PubMed ID: 18280812
    [No Abstract]   [Full Text] [Related]  

  • 17. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
    Cappellini A; Mongiorgi S; Finelli C; Fazio A; Ratti S; Marvi MV; Curti A; Salvestrini V; Pellagatti A; Billi AM; Suh PG; McCubrey JA; Boultwood J; Manzoli L; Cocco L; Follo MY
    FASEB J; 2020 Nov; 34(11):15400-15416. PubMed ID: 32959428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.
    Mongiorgi S; Follo MY; Yang YR; Ratti S; Manzoli L; McCubrey JA; Billi AM; Suh PG; Cocco L
    Curr Pharm Des; 2016; 22(16):2345-8. PubMed ID: 26916022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.